- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04898686
Probiotic Chewables in Allergic Rhinoconjunctivitis Patients
April 7, 2022 updated by: Sarah Lebeer, University Hospital, Antwerp
Study of the Probiotic Potential of a Lacticaseibacillus Strain in the Upper Airways in Patients With Allergic Rhinoconjunctivitis After Administration in a Chewable
With this double- blind, randomised, placebo-controlled study, the investigators want to investigate the influence of a chewable with the probiotic strain Lacticaseibacillus rhamnosus GG on the symptoms and immunological markers of allergic rhinoconjunctivitis (AR).
In addition, the investigators aim to study the influence of this probiotic chewable on the microbiome of the upper respiratory tract after administration in adults with AR.
The bacterial and cytokine profiles in the naso- and oropharynx will be monitored before, during and after the treatment.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
64
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Edegem, Belgium
- Antwerp University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adults aged 18 at the time of registration;
- Seasonal allergic rhinoconjunctivitis (AR) in the context of grass pollen allergy diagnosed on the basis of anamnesis cfr. ARIA guidelines and positive skin prick test and / or immunocap assay;
- Positive skin prick test (SPT) for grass pollen and / or the presence of specific IgE for grass pollen, confirmed by a medical specialist, measured at the start of the study: Soluprick SQ Phleum pratense pollen 10 HEP - ALK and / or IgE specific immunocap assay Phleum pratense (timothy grass) (g6);
- Body Mass Index in the range of 19-32 kg / m2;
- Instructed during screening and agreed not to use other probiotic products outside of the study during the study period;
- Signed the consent form.
Exclusion Criteria:
- Antibiotic use at baseline and during the study;
- Pregnant women;
- Unstable / uncontrolled asthma (to be determined by investigator-physician);
- Sensitization to dust mites
- History of probiotic use in the past two weeks;
- Current diagnosis of cancer or immunosuppressive therapy within the past 6 months;
- Abnormalities of the oral mucosa;
- Acute and chronic infectious and inflammatory upper airway diseases (eg acute / chronic rhinosinusitis cfr. EPOS guidelines);
- Clinically significant bleeding disorder;
- Any other medical condition that, in the principal investigator's opinion, warrants exclusion from the trial;
- History of regular use (> 3 days out of 7) of tobacco products within the previous two weeks
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Probiotic group
daily use of a probiotic chewable for 8 weeks
|
chewables containing Lacticaseibacillus rhamnosus GG
|
Placebo Comparator: Placebo group
daily use of the placebo chewable for 8 weeks
|
chewables without probiotic strain.
Ingredients: Xylitol, microcrystalline cellulose, stearic acid, natural orange flavor, silica, magnesium stearate, citric acid and malic acid.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Transfer of L. rhamnosus GG (estimated CFU counts) to the oronasopharyngeal cavity after administration of the chewable
Time Frame: at 8 weeks
|
qPCR
|
at 8 weeks
|
Changes in the score of allergic rhinitis symptoms
Time Frame: over the study period (= 10 weeks)
|
Daily questionnaires will be used, in which a self-reported Total Nasal Symptom Score (TNSS) based on rhinorrhea, nasal congestion, nasal itching and sneezing with symptom severity ranging from 0 (no problem) to 12 (very severe problem) will be recorded.
|
over the study period (= 10 weeks)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
changes in microbiome of the oronasopharyngeal region after administration of the chewable
Time Frame: baseline, 8 weeks
|
16S rRNA amplicon sequencing
|
baseline, 8 weeks
|
Inlfuence on general nose- and mouth health
Time Frame: baseline, 8 weeks, 10 weeks
|
A clinical evaluation by an ENT specialist will be performed at the start and 8 weeks of the study to assess the general nose and mouth health of the participants.
Questions on discomfort and symptoms of inflammation or infection in the nose and mouth will be included in the Sino-Nasal Outcome Test (SNOT-22)-based questionnaire implemented at the start, week 8 and week 10.
Symptoms will be scored from 0 (no problem) to 5 (very severe problem)
|
baseline, 8 weeks, 10 weeks
|
Changes in the absolute numbers of specific airway pathogens and viruses
Time Frame: baseline, 8 weeks
|
qPCR
|
baseline, 8 weeks
|
Changes in cytokine levels (e.g. IL-10, IL-4, IL-5, IL-13) in oro- and nasopharynx samples, and cytokine and antibody levels in blood samples
Time Frame: baseline, 8 weeks
|
qPCR and/or ELISA
|
baseline, 8 weeks
|
Frequency of medication use
Time Frame: over the study period (= 10 weeks)
|
Daily questionnaires will be used where the type and frequency of medication use should be recorded
|
over the study period (= 10 weeks)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Sarah Lebeer, Prof, Universiteit Antwerpen
- Principal Investigator: Olivier Vanderveken, Prof, University Hospital, Antwerp
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
August 1, 2020
Primary Completion (Actual)
August 6, 2021
Study Completion (Actual)
August 6, 2021
Study Registration Dates
First Submitted
April 28, 2021
First Submitted That Met QC Criteria
May 19, 2021
First Posted (Actual)
May 24, 2021
Study Record Updates
Last Update Posted (Actual)
April 15, 2022
Last Update Submitted That Met QC Criteria
April 7, 2022
Last Verified
April 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- B3002020000086
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergic Rhinoconjunctivitis
-
Medical University of GrazRecruiting
-
Immunomic Therapeutics, Inc.Completed
-
University of ZurichCompletedAllergic RhinoconjunctivitisSwitzerland
-
ALK-Abelló A/SCompletedAllergic RhinoconjunctivitisSpain
-
ALK-Abelló A/SCompletedAllergic RhinoconjunctivitisSpain
-
Immunomic Therapeutics, Inc.CompletedAllergic RhinoconjunctivitisUnited States
-
ALK-Abelló A/SCompleted
-
Cytos Biotechnology AGCompletedHouse Dust Mite Allergy | Perennial Allergic Rhinoconjunctivitis
-
Cytos Biotechnology AGCompletedHouse Dust Mite Allergy | Perennial Allergic RhinoconjunctivitisSwitzerland
-
ClinNovis GmbHCompletedRhinoconjunctivitis, AllergicGermany
Clinical Trials on Probiotic chewables
-
King's College Hospital NHS TrustCompleted
-
Fudan UniversityInner Mongolia Yili Industrial Group Co., LtdCompletedObesity | AdiposityChina
-
Maastricht University Medical CenterCompleted
-
Universiti Kebangsaan Malaysia Medical CentreUnknownHypertension | Obesity | Type 2 Diabetes Mellitus | HyperlipidemiaMalaysia
-
BiocodexCompletedAcute GastroenteritisArgentina
-
Fundació Sant Joan de DéuCompleted
-
University of LeedsUnknown
-
Centro Pediatrico Albina de PatinoCompletedAcute Gastroenteritis | Acute DiarrheaBolivia
-
Shandong UniversityUnknownGastrointestinal Neoplasms | Colorectal Cancer | Malnutrition | Effects of Chemotherapy | Tumor ImmunityChina
-
Deivis de Oliveira guimaraesCompletedParkinson Disease | Alzheimer DiseaseBrazil